Prevention of Diastolic Dysfunction Caused by Doxorubicin by Mitochondrial Antioxidant Plastomitin
Autor: | Valery I. Kapelko, Vladimir L. Lakomkin, E. V. Lukoshkova, A A Abramov, A. V. Prosvirnin |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
Antioxidant medicine.medical_treatment Diastole Cardiomyopathy 030204 cardiovascular system & hematology Antioxidants Ventricular Function Left Contractility 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Animals Humans Doxorubicin 030212 general & internal medicine Cardiac catheterization Heart Failure Ejection fraction business.industry medicine.disease Rats Heart failure Cardiology Cardiomyopathies Cardiology and Cardiovascular Medicine business medicine.drug |
Zdroj: | Kardiologiia. 60:98-102 |
ISSN: | 2412-5660 0022-9040 |
Popis: | Aim An attempt to prevent the development of diastolic dysfunction (DD) with the mitochondrial antioxidant plastomitin on a model of doxorubicin-induced cardiomyopathy. DD is a type of chronic heart failure. Due to the increasing number of patients with this condition and the absence of effective therapy, development of means for DD correction is a relevant objective.Material and methods Cardiomyopathy was modeled in 17 rats by two subcutaneous injections of doxorubicin 2 mg/kg/week. The other group (n=17), also administered with doxorubicin, received plastomicin 0.32 mg/kg daily subcutaneously. Left ventricular function was evaluated with echocardiography (EchoCG) and cardiac catheterization with simultaneous pressure and volume monitoring.Results According to EchoCG data the ejection fraction remained unchanged in the experimental groups. Cardiac catheterization showed disorders of both myocardial contractility and relaxability only in the doxorubicin group.Conclusion A course of plastomitin in combination with the doxorubicin treatment can maintain normal heart contractility and thereby, prevent the known doxorubicin cardiotoxicity. |
Databáze: | OpenAIRE |
Externí odkaz: |